Literature DB >> 15302105

Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.

José López-Sendón1, Karl Swedberg, John McMurray, Juan Tamargo, Aldo P Maggioni, Henry Dargie, Michal Tendera, Finn Waagstein, Jan Kjekshus, Philippe Lechat, Christian Torp-Pedersen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15302105     DOI： 10.1016/j.ehj.2004.06.003

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  50 in total

Review 1.  The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.

Authors:  Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2010-04       Impact factor: 5.369

Review 2.  Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.

Authors:  Risto S Cvetković; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Best practice in primary care pathology: review 6.

Authors:  W S A Smellie; J Forth; J J Coleman; W Irvine; P C Dore; G Handley; D G Williams; P J Galloway; K G Kerr; R Herriot; G P Spickett; T M Reynolds
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

4.  Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Carlo Maria Cipolla
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-12

Review 5.  [Secondary prevention after myocardial infarction].

Authors:  J E Pflumm; T Pomykaj; M P Heintzen
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

Review 6.  Novel therapeutic targets for the treatment of heart failure.

Authors:  Juan Tamargo; José López-Sendón
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

7.  Revealed Opportunism: How Physicians "Game" Prior Authorization Protocols Until They Are Rescinded.

Authors:  Natan R Kahan; Dan-Andrei Waitman; David P Chinitz
Journal:  Am Health Drug Benefits       Date:  2016-09

8.  Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction.

Authors:  Morten L Hansen; Gunnar H Gislason; Lars Køber; Tina Ken Schramm; Fredrik Folke; Pernille Buch; Steen Z Abildstrom; Mette Madsen; Søren Rasmussen; Christian Torp-Pedersen
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

9.  Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.

Authors:  Niteesh K Choudhry; Soko Setoguchi; Raisa Levin; Wolfgang C Winkelmayer; William H Shrank
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-12       Impact factor: 2.890

Review 10.  New Targets in the Drug Treatment of Heart Failure.

Authors:  James A Iwaz; Elizabeth Lee; Hermineh Aramin; Danilo Romero; Navaid Iqbal; Matt Kawahara; Fatima Khusro; Brian Knight; Minal V Patel; Sumita Sharma; Alan S Maisel
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.